Abstract:Our results showed that this new chip had an important clinical value of patients with metastatic breast cancer.CTCs count showed good prospects in monitoring cancer prognosis and guiding future individualized treatment.We have manufactured a new microfluidic chip to isolate and identify CTCs and CTCs clusters with high throughput.Circulating tumor cells (CTCs) existing in peripheral blood can be used to predict the prognosis and survival of cancer patients. The study was designed to detect circulating tumor cells and circulating tumor single cell genes by applying microfluidic chip technology. It was used to explore the clinical application value in breast cancer.We have developed a size-based CTCs sorting microfluidic chip, which contains a hexagonal array and a micro-pipe channel array to isolate and confirm both single CTCs and CTCs clusters. The sorting performance of the as-fabricated chip was tested by analyzing the clinical samples collected from 129 breast cancer patients and 50 healthy persons.In this study, the chip can detect different immunophenotypes of CTCs in breast cancer patients. It was found that the new microfluidic device had high sensitivity (73.6%) and specificity (82.0%) in detecting CTCs. By detecting the blood samples of 129 breast cancer patients and 50 healthy blood donors, it was found that the number of CTCs was not associated with clinical factors such as age, gender, pathological type, and tumor size of breast cancer patients (P > 0.05), but was associated with TNM staging of breast cancer, with or without metastasis (P < 0.005). There was a statistically significant difference in the number of CTCs between luminal A (ER+/PR+/HER2-) and HER-2+ (ER-/PR-/HER2+) (P < 0.05). The best cut-off level distinguished by CTC between the breast cancer patients and the healthy persons was 3.5 cells/mL, with 0.845 for AUC-ROC, 0.790–0.901 for 95% CI, 73.6% for sensitivity, and 82% for specificity (P = 0.000). The combination of CTC, CEA, CA125 and CA153 can provide more effective breast cancer screening.The CTCs analysis method presented here doesn't rely on the specific antibody, such as anti-EpCAM, which would avoid the missed inspection caused by antibody-relied methods and offer more comprehensive biological information for clinical breast cancer diagnosis and treatment.

Accurate Isolation of Circulating Tumor Cells via a Heterovalent DNA Framework Recognition Element-Functionalized Microfluidic Chip

Self-Sterilizing and Regeneratable Microchip for the Precise Capture and Recovery of Viable Circulating Tumor Cells from Patients with Cancer.

Programmable DNA-responsive Microchip for the Capture and Release of Circulating Tumor Cells by Nucleic Acid Hybridization

Enhanced Isolation and Release of Circulating Tumor Cells Using Nanoparticle Binding and Ligand Exchange in a Microfluidic Chip.

Combination of Antibody-Coated, Physical-Based Microfluidic Chip with Wave-Shaped Arrays for Isolating Circulating Tumor Cells

Antibody-Functional Microspheres Integrated Filter Chip with Inertial Microflow for Size-Immune-Capturing and Digital Detection of Circulating Tumor Cells.

Isolation and Retrieval of Circulating Tumor Cells on A Microchip with Double Parallel Layers of Herringbone Structure

Dual-Multivalent-Aptamer-Conjugated Nanoprobes for Superefficient Discerning of Single Circulating Tumor Cells in a Microfluidic Chip with Inductively Coupled Plasma Mass Spectrometry Detection.

Multifunctional Gelatin Nanoparticle Integrated Microchip for Enhanced Capture, Release, and Analysis of Circulating Tumor Cells

Designer tetrahedral DNA framework-based microfluidic technology for multivalent capture and release of circulating tumor cells

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip

Multifunctional Gelatin-Nanoparticle-Modified Chip for Enhanced Capture and Non-Destructive Release of Circulating Tumor Cells

A label-free microfluidic chip for the highly selective isolation of single and cluster CTCs from breast cancer patients

Three-Dimensional microfluidic chip with twin-layer herringbone structure for high efficient tumor cell capture and release via Antibody-conjugated magnetic microbeads.

Bioinspired Engineering of a Multivalent Aptamer‐Functionalized Nanointerface to Enhance the Capture and Release of Circulating Tumor Cells

Highly Efficient Capture and Harvest of Circulating Tumor Cells on A Microfluidic Chip Integrated with Herringbone and Micropost Arrays

Rapid and Efficient Capturing of Circulating Tumor Cells from Breast Cancer Patient's Whole Blood Via the Antibody Functionalized Microfluidic (AFM) Chip

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells.

Precisely Enumerating Circulating Tumor Cells Utilizing a Multi-Functional Microfluidic Chip and Unique Image Interpretation Algorithm.

Nanoroughened Adhesion-Based Capture of Circulating Tumor Cells with Heterogeneous Expression and Metastatic Characteristics.

A chip assisted immunomagnetic separation system for the efficient capture and in situ identification of circulating tumor cells